Reply to the letter ‘Effectiveness of COVID-19 vaccines against Omicron variant’
Response or Comment
This is about the Letter to the Editor entitled ‘Effectiveness of COVID-19 vaccines against Omicron variant’  in response to the published review ‘A global picture: therapeutic perspectives for COVID-19’ . Since the publication of the review, we submitted a commentary article entitled ‘Therapeutics to tackle Omicron outbreak’, which was recently accepted in Immunotherapy . This commentary article covers various therapeutics required to manage the Omicron outbreak. Following the worldwide dissemination of the SARS-CoV-2 Omicron BA.2 lineage, various BA.2-related variations with mutations in the L452 residue of the spike protein, such as BA.2.9.1 and BA.2.13 (L452M), BA.2.12.1 (L452Q) and BA.2.11, BA.4 and BA.5 (L452R), appeared in several nations . The World Health Organization (WHO) designated B.1.1.529 as a variant of concern and it was named the Omicron variant. Omicron is different, highly transmissible, and potent new variant of SARS-CoV-2 due to the high number of mutations. Omicron was first identified in South Africa in November 2021 .
Chavda, V. P., Soni, S., Prajapati, R., Yallapu, M. M., & Apostolopoulos, V. (2022). Reply to the letter ‘Effectiveness of COVID-19 vaccines against Omicron variant’. Immunotherapy, (0). https://doi.org/10.2217/imt-2022-0135
Immunology and Microbiology